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Intravenous injections of 25.5 nmol rat amylin into fasted anesthetized rats caused a rapid increase in plasma lactate followed by an increase in 
plasma glucose; there was a transient fall in blood pressure. Subcutaneous injection of 25.5 nmol amylin also caused increases in lactate and glucose 
but did not change blood pressure. Similar responses were observed during somatostatin infusion and in the absence of changes in catecholamines. 
These results fit with a scheme in which amylin elicits muscle glycogenolysis, release of lactate, and increased hepatic gluconeogenesis due to 
increased supply of substrate. 
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1. INTRODUCTION 
Amylin is a 37 amino acid protein which is the major 
constituent of the islet amyloid found in patients with 
type 2 (non-insulin-dependent) diabetes mellitus [l]. 
Amylin is synthesized in islet p-cells and secreted along 
with insulin in response to nutrient stimuli [2]. Amylin 
has reported biological effects in a range of tissue tar- 
gets including skeletal muscle [3], bone [4], liver [5] and 
the pancreas [6]. In skeletal muscle, amylin was found 
to inhibit the incorporation of radiolabelled glucose 
into glycogen [7], to inhibit glycogen synthase [8] and to 
activate glycogen phosphorylase [S]. During euglycemic 
hyperinsulinemic glucose clamp studies, amylin reduces 
peripheral glucose disposal and opposes insulin-mediat- 
ed suppression of hepatic glucose production [ 10,111. 
Amylin has also been reported to have an hypoten- 
sive action [ 12,133. Previous studies of amylin actions in 
vivo have mostly looked at the ability of amylin to 
modulate insulin-mediated metabolic changes, and 
none of the studies have included measurement of both 
metabolic and cardiovascular variables in the same 
preparation. While other studies have generally looked 
at the ability of amylin to modulate insulin-mediated 
metabolic changes, the present study reports the meta- 
bolic response to amylin aione, with or without somato- 
statin infusions to inhibit secretion of other pancreatic 
and pituitary hormones. We have used li.ghtly ha- 
lothane- anesthetized rats fasted for 18 11. These animals 
are depleted in liver glycogen due to the fasting state, 
and provide a stable preparation for measurements over 
many hours. 
Both intravenous and subcutaneous injections of 25.5 
nmol amylin cause rapid increases in plasma lactate, 
followed by increases in plasma glucose. We have pro- 
posed that amylin acts primarily to cause glycogenolysis 
in skeletal muscle, with increased production of glucose- 
6-phosphate, increased glycolysis, and increased pro- 
duction and release of lactate; this lactate could then 
serve as a substrate for hepatic gluconeogenesis. As one 
test of this idea, lactate infusions were given to mimic 
the increases in plasma lactate caused by amylin, and 
the glucose increment thus produced was compared 
with that evoked by amylin. The data reported here are 
consistent with this proposal. The metabolic actions of 
amylin appear to be independent of changes in blood 
pressure, insulin, or the main, rapidly acting counter- 
regulatory hormones. 
2. MATERIALS AND METHODS 
2. I . Attittds 
Male Harlan-Sprague-Dawley rats (body mass 33X+7 g, age 90+3 
days) wcrc housed at 22,7+OPC in a l2:12 hour light:dark cycle 
(experiments being performed during the light cycle) and fed and 
watered ad libitum (Diet LM-485, Teklad, Madison, WI). Experi- 
ments were performed after a fast of 19+0,4 h. There were 5 treatment 
groups. All animals were treated identically in regard to surgery, 
instrumentation, blood withdrawal and infusion of fluids. The treat- 
ment groups were as follows: 
I. Intravenous amylin bolus with somatostatin infusion (n=6). After 
2.hours infusion with somatostatin (S-9129, Sigma, St Louis, MO) 
at 3.4 nmolW, which then continued throughout the experiment. 
animals were injcctcd with a 100/11 50 mM NaCl containing 25.5 
nmol freshly dissolved rat amylin (IoI# ZG485, Bachem, Torrance, 
CA), The biological activiky of peptidc to be used in this study was 
first verilicd using the solcus muscle-based assay [14] (E&,=6.7* 1‘5 
nM). 
Cbrr~l.s/tott~/~tirc ar/dtm.r: AA. Young, Amylin Corporation, Depart- 2. Intravenous amylin bolus without somatostatin infusion (n-7). 
mcnt of Physiology, 9373 Townc Ccntrc Drive, San Diego. CA 92121, Animals were injected with an intravenous bolur of 25.5 nmol rat 
USA. Fax: (I) (619) 5.52 2212. emylin in 100 PI saline a5 for group I, 
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3. Subcutaneous amylin injection without somatostatin infusion 
(n=5). Animals were injected under the abdominal skin with 25.5 
nmol rat amylin in 100 PI saline. 
4. lntravenous primed/continuous infusion of sodium lactate (~3). 
Animals were infused intravenously with 875 mM Na lactate in 
saline (pH 7.0) at I S ml/h for 1 h. A 0.5 ml bolus was delivered 30 
min after the start of infusion, This protocol attempted to replicate 
the plasma lactate profile observed following amylin administra- 
tion. 
5. Controls (n=l2). Rats pre-infused with somatostatin (as in group 
I) were injected with 25.5 nmol amylin that had been autoclawed at 
121°C for 90 min (n-3) or with saline alone 0~3). Rats not infused 
with somatostatin were injected with saline alone (~6). Since there 
were no differences between responses to any of these treatments, 
data have been pooled into a single control group. 
2.2. Strr~erIt/inslrtrtnenmtinti 
Anesthes‘ia was induced with 5% halothane, maintained at 2% 
during surgery and at O.&l% during metabolic recordings. Tracheo- 
tomy and cannulation of the right femoral artery and saphenous vein 
enabled recording of arterial pressure (Spectramed P23XL transducer, 
model 13-4615-58 amplilier, Gould. Cleveland, OH) and intravenous 
infusion. Signals for mean arterial pressure were sampled and stored 
with It-bit precision at I Hz using a computerized data acquisition 
system (DT2801A A/D converters, DataTranslation, Marlboro, MA; 
AST Premium 386 computer, AST Research, Irvine, CA; Labtech 
Notebook software, Laboratory Technologies Corp, Wilmington, 
MA). Colonic temperature was measured and controlled using a ther- 
mistor probe and controller (Model 73A, YSI. Yellow Springs, OH) 
connected to a heated operating table. 
Arterial samples were drawn OS, 0.25 and 0 h before bolus injection, 
and 0.5, I, 1.5.2,3 and 4 h after injection. Samples were collected into 
heparinized capillaries. centrifuged, and the separated plasma analy- 
zed for glucose, lactate, insulin and in some cases, catecholamines and 
amylin. All chemicals were of analytical grade or better. 
Glucose and lactate were analyzed immediately by immobilized 
enzyme chemistries (glucose oxidase, L-lactate oxidase, Analyzer 
model 2300-STAT, YSI, Yellow Springs, OH), 
Insulin was determined by radioimmunoassay (Micromedic human 
insulin RIA kit, ICN Biomedicals, Horsham, PA), sensitivity 6 pM, 
cross-reactivity to rat insulin 89.5%. Rat amylin was dctcrmined by 
radioimmunoassay of whole plasma (antibody RAS 7323-N. lot# 
019166-1, Peninsula Laboratories, Relmont, CA) using as standards, 
rat amylin (lot #ZG48.5, Bachem, Torrance, CA) added to plasma of 
rats previously made diabetic by intravenous injection of 65 mg/kg 
strcptozotocin. 
Plasma catecholamines (epinephrine and norepinephrine) were 
measured at 0, 2 and 4 h post-injection using HPLC with electrochc- 
mica1 detection following plasmaextraction with alumina, A modifica- 
tion of the method of Weickcr et al. [IS], whereby internal standard 
(dehydroxybutyric acid) was added to plasma prior to extraction ena- 
bled analysis of 50~1 samples with an intra-assay cocfficicnt of varia- 
tion of 8,l%. 
2.4. Numericd ttdtds 
Results arc prcscntcd as means *SEM. Pairwisc comparisons wcrc 
pcrformcd using paired or unpaired I-test routines contuincd within 
the SYSTAT program [lb]. 
3. RESULTS AND DISCUSSION 
Fig. 1 shows the plasma lactate and glucose ccmcen- 
trntions that follow intravctlous injections of25,S nmd 
rat anlylin (open circles), Amylin clicitcd an approxima- 
tely 3-fold rise in lactate, which was maximal by 30 min, 
and returned to the basal level at 3 h. There was also 
a rise in glucose from 5.9kO.3 ml&I to ll.Ok0.6 mM. It 
was maximal between 1 and 2 h and was still above the 
control level at 4 h. These data, and more detailed mea- 
surement of the early time course (Wang and Young, 
unpublished data) indicated that the plasma lactate in- 
crease precedes that of glucose. The dotted lines show 
the control response in animals injected with saline vehi- 
cle alone; there was a slow rise in plasma glucose, con- 
sistently seen during the 6 h following surgery, but no 
change in plasma lactate. 
Amylin activates muscle glycogen phosphorylase by 
conversion to the active a-form [8,9]. This action of 
amylin may contribute to the increased muscle lactate 
production in vitro [7], increased glucose-6-phosphate 
concentration [17], and decreased total glycogen con- 
tent [I73 following amylin stimulation. The appearance 
of lactate in the plasma following amylin administration 
in this study is consistent with amylin-induced muscle 
glycogenolysis. 
3.2. Intravenous arnyiin injections during infusion of so- 
rnatostatin 
The increases in lactate and glucose concentration 
elicited by amylin could have been accompanied by, or 
in part caused by, changes in other hormones, such as 
insulin and glucagon. Therefore, the effects of intrave- 














Hours after amylin injection 
Fig, I, Plasftlil glucose and lactate concentrations following amylin 
:~tlministration. Arterial glucoac (upper panel). and IncIate conccntra- 
lion (lower panel) following 25.5 nmol amytin: i.v, with SottlHIOSliItill 
prcinftraion (e): i.v. without somatostatin ( .I: subcutaneous (0). The 
broken lint shows the control response. Symbols rcprcscnt nwa~ls 
ssm. ,F5-12. 
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Table I CGRP (CGRP,) receptor. Amylin is nearly 50% homo- 
Hormonal levels logous with calcitonin gene-related peptide, the most 
Time Insulin 
potent vasodilator yet described [l&l. Indeed, we [12] 
Epinephrine Norepine- 
(h) WV WW phrine 
and others [13] have demonstrated that the hypotensive 
(nW 
effect of amylin can be blocked by the co-administration 
of the CGRP-antagonist, 8s37hCGRP. 
Amylin injected 
(somatostatin 3.4. Plasma anzylin concentrations and sequence qf arny- 
preinfusion) 
_ . 
0.0 1 Y 1.0 k 44.4 2.67 Y!Z 0.55 3.99 f 0.29 
lin-mediated events 
2.0 152.4 + 40.8 2.73 + 1.09 2.38 + 0.97 The time course of plasma amylin concentration fol- 
4.0 99.6 C 27.0 1.91 + 0.82 2.38 f 1.12 lowing intravenous injection of 25.5 nmol was assessed 
Control 
0.0 133.2 + 43.8 3.06 rf: 0.71 3.=99 I? 0.63 
2.0 170.4 2 25.8 4.15 zk 0.38 3.79 1: 0.34 
4.0 218.4 t 49.8 4.09 -t 0.98 3.99 + 0.53 
somatostatin, which is established as an inhibitor of 
endocrine secretion, including secretion of glucagon 
and insulin from pancreatic islets. The results are shown 
in Fig. 1, by the closed circles. ‘Pancreatic clamping’ by 
somatostatin changed the response very little from that 
observed in the absence of somatostatin; the return of 
glucose concentrations towards control levels was 
somewhat faster. Table I shows that insulin levels did 
not increase following amylin injection in somatostatin- 
infused animals. In contrast, we found in a subsequent 
study (using a different insulin assay) that plasma insu- 
lin was increased 2.3-fold 1 h after intravenous injection 
of amylin. Thus, it appears that somatostatin infusion 
inhibited insulin secretion in these experiments. awing 
to necessary limitation of sample volumes, glucagon 
levels were not measured. However, glucagon does not 
increase plasma lactate and so could not have produced 
that particular amylin effect under the present experi- 
mental conditions. 
in 2 r&s which were treated identically to those in group 
2, except that plasma samples were drawn more fre- 
quently. The decay curve could be fitted to 2 exponen- 
tials, the principal one decaying from an initial extrapo- 
lated plasma concentration of 33 nM with a tllZ of 12.5 
min, the minor second one decaying with a tlR of 69 
min. The rapidity and transience of the hypotension and 
appearance of lactate after amylin injection mirrors the 
decay of plasma immunoreactivity. The slower and 
more prolonged increases in plasma glucose following 
amylin injection and following lactate infusion may re- 
fleet a limited capacity to process the lactate and glucose 
released into the blood. The observed sequence of chan- 
ges in plasma lactate and glucose indicate that the hy- 
perglycaemia may be a consequence of the hyperlactae- 
mia, but that the reverse is unlikely to be the case. 
3.5. Subcutaneous infection of ainylin 
Fig. 1 shows (open squares) the increases in plasma 
lactate and glucose following subcutaneous injection of 
25.5 nmol amylin. There was an approximately 2.2-fold 
increase in plasma lactate which preceded an increase 
of plasma glucose from 5.57-1-0.44 mM to 9.9650.51 
mkl. These responses were slightly delayed compared 
with response to intravenous injections - as expected 
Also shown in Table 1 are measurements of plasma 
catecholamines. In the somatostatin-infused animals, 
amylin injections did not lead to an increase in epine- 
phrine or norepinephrine; the levels remained close to 
control values. Thus, it appears that amylin’s actions do 
not result from increased circulating catecholamines. 
This view is supported by the failure of amylin infusion 
to change such hormones [I 11, 
3.3. Bloor~p1~w14~e w.s~~ot~sc 10i~ttravemu uruyiirl k&c- F 40 - 
tiorl 6 
Changes in mean arterial pressure following amylin P 
administration are shown in Fig. 2, Rats receiving an 
intrnvcnous bolus of 25.5 nmol amylin (with or without 0 
prior somatostatin infusion) showed a fall in mean arte- 0 1 2 3 4 
rial prcssurc of around 35 mmlig within 1 min of injcc- Hol;:s after amylin injection 
tion. Mood pressure then returned to preinjection levels Fig. 2. Acute blood prcssurc response. Mean arterial prcssurc ror rats 
over the next 30 min, illjcckd with 25.5 nmol amylin: (>:. /r=C) inlravcnous injection (no 
The hypotensivc action of amylin in the present stud- 
sowtostatitl prcinl’usiou), (~3. 1~2) subcutaneous injection. Symbols 
irs is consistent with ali acute action at the vascular 
arc mcuns SEM. TIC fawn continuous record is pldtkd far thr first 
30 niiu ill each group. 
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[21,%2], it nonetheless appears to inhibit insulin’s hepa- 
tic effects, including suppression of glucose production 
[IO,1 I] and stimulation of hepatic glycogen synthase [5]. 
3.7. Concll4sion 
Amylin, independent of the effects of counter-regula- 
tory hormones or of changes in blood pressure, causes 
increases in plasma lactate concentration and slower 
increases in plasma glucose concentration. This se- 
quence of changes, combined with the increases in plas- 
ma glucose seen following lactate infusion, suggests that 
the observed increases in plasma glucose are a con- 
sequence of amylin-induced hyperiactaemia. 
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